Compare IDEXX Laboratories, Inc. (IDXX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs KB Financial Group, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while KB Financial Group, Inc. trades at $123.07 (market cap $42.62B). The key difference: IDEXX Laboratories, Inc. and KB Financial Group, Inc. are close in size by market cap, and KB Financial Group, Inc. pays a 2.71% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and KB Financial Group, Inc. for 33 Days on average.
| IDXX | KB | |
|---|---|---|
Market Cap | $40.43B | $42.62B |
Volume | 692,164 | 164,291 |
Sector | Health | Financials |
52-Week High | $766.68 | $132.88 |
52-Week Low | $504.70 | $77.50 |
Typical Hold Time | 46 Days | 33 Days |
Enterprise Value | $41.32B | $215.53T |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
KB Financial Group (KB) trades at $122.04, down 2.16% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.68, P/B of 0.94, and consistent earnings beats in recent quarters. Revenue grew from $17.77T in 2022 to $21.23T in 2025, with net income rising to $5.83T. Operating cash flow improved significantly to $4.23T in 2025, while analyst consensus shows 33% buy ratings amid positive momentum coverage.
KB presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term consolidation. Key risks include market volatility and execution challenges in non-banking expansion. The stock's current price near support levels and strong institutional interest support a cautiously optimistic outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
